Red Light Holland and ASX-listed Creso Pharma are merging to form HighBrid Lab. TRIP CEO Todd Shapiro to lead the combined entity.
Exploring the companies and themes that make up this emerging and exciting new sector
Cybin Selects Anxiety Disorder Indications for Proprietary Psychedelic Molecule CYB004
Cybin's latest R&D initiative (CYB004) is a proprietary molecule targeting anxiety disorders.
Mydecine Unveils Artificial Intelligence Drug Discovery Program
Mydecine announces a new program to incorporate AI "machine learning" into its drug R&D.
‘I’m a lighter me’: Can Mike Tyson and psychedelics help boxers with brain trauma?
The former heavyweight champion says psychedelics would have helped him with his mental health during his career. Some scientists and companies agree
Getting People to Help Changes Everything: William Cook, CEO of MindLeap
Mydecine Innovations Group is a psychedelics company that The Dales Report has been watching closely this past year.
MindMed’s New CEO Well-Prepared For Next Stage of Corporate Development
Co-Founder JR Rahn has stepped down as CEO of MindMed. His replacement, Robert Barrow, brings a wealth of clinical trials experience.
Entheon Biomedical's Wholly-Owned Subsidiary, HaluGen Life Sciences, Psychedelics Genetic Test Kit Now Available for Sale in US
HaluGen Life Sciences' test evaluates an individual's overall sensitivity and risk profile associated with psychedelic-assisted therapy
Magic Mushrooms Helped Me Cope With Postpartum Depression
In 2014, during my first pregnancy, I felt happy and healthy almost all the time.
MindMed Announces Chief Executive Officer Transition
JR Rahn is stepping down as MindMed's CEO, to be replaced by Chief Development Officer, Robert Barrow.
Are Psychedelics The Ultimate Brain-Repair Drugs?
Psychedelic drugs increasingly appear to be powerful medicinal tools to rebuild broken brains.
Field Trip Health Ltd. Applies to List Its Common Shares on the NASDAQ Stock Market
After just uplisting to the TSX in Canada, Field Trip Health has applied to uplist to the NASDAQ in the U.S.
Mydecine Discovers Over 40 Groundbreaking Potential Pharmacologically Active Novel Compounds in Mushrooms
Mydecine announces identifying 40 previously unknown "novel compounds" among dozens of mushroom species it has screened.